(Q37856088)

24 August 2017

1 reference

title

Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints (English)

1 reference

24 August 2017

1 reference

0 references

John D Turnidge

1

1 reference

24 August 2017

Subcommittee on Antimicrobial Susceptibility Testing of the Clinical and Laboratory Standards Institute

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

Clinical Infectious Diseases

24 August 2017

published in

1 reference

24 August 2017

volume

52

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

917-924

1 reference

Should we reevaluate antibiotic breakpoints?

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Setting and revising antibacterial susceptibility breakpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Pharmacokinetics and Clinical Use of Cephalosporin Antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Clinical studies of cefazolin and comparison with other cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Evaluation of cefazolin, a new cephalosporin antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Treatment with Cefazolin in 45 Cases of Urinary Tract Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Cefamandole and Cefazolin in the Therapy of Complicated Urinary Tract Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Pyelonephritis in pregnancy: once-a-day ceftriaxone versus multiple doses of cefazolin. A randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

A randomized trial of three antibiotic regimens for the treatment of pyelonephritis in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Clinical and in vitro evaluation of cefazolin, a new cephalosporin antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Prospective Comparison of Cefoxitin and Cefazolin in Infections Caused by Aerobic Bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

Cefazolin in the treatment of acute enteric fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR031

21 January 2018

Identifiers

DOI

10.1093/CID/CIR031

1 reference

24 August 2017

1 reference